The North Carolina Biotechnology Center leads life sciences economic development for North Carolina by supporting the progression of ideas from research lab to the marketplace. NCBiotech invests in ...

Healthcare systems must turn proven research into patient care faster with practical infrastructure, product champions, trust ...

A recent Executive Order (EO) de-risks psychedelic drug development by clarifying regulations, but scalable treatment models ...

In a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.

A “Godzilla” El Niño could disrupt pharma supply chains, pushing life sciences firms toward AI-driven weather forecasting, ...

On this week's episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in ...

Industry Explorers Blaze On: A series of stories of longtime leaders, still active in the industry, sharing their historical perspectives on life sciences industry innovation. A consuming interest, ...

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

Life Science industry experts from Life Science Leaders editorial advisory board answer your questions ...

As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large ...

We are now well into what is often called the “psychedelic renaissance,” and the field has made genuine progress alongside all the early excitement. Many groups new to the realities of FDA oversight ...